Tag iressa [52 articles] Export Sort

Recent papers classified by the tag iressa.

Hide details

	Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance? [My Copy] The oncologist, Vol. 13, No. 9. (September 2008), pp. 933-944. by Thomas E. Stinchcombe, Mark A. Socinski posted to nsclc lung iressa gefitinib cancer by nicedoc on 2009-08-17 04:12:17 as
	Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. [My Copy] Breast cancer research and treatment, Vol. 87, No. 2. (September 2004), pp. 167-180. by N. J. Jordan, J. M. Gee, D. Barrow, A. E. Wakeling, R. I. Nicholson posted to aktpkb breast cancer egf egfr erbb2gefitibin iressa mcf-7 pi3k resistance tamoxifen zd1839 by SChewchuk on 2009-04-28 15:12:26 as
	The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer. [My Copy] The oncologist, Vol. 10, No. 7. (August 2005), pp. 467-470. by R. L. Comis posted to cancer erlotinib gerifinib iressa lung lungcancer nsclc tarceva by holympus on 2009-04-21 15:43:49 as
	Tyrosine kinase blockers: new hope for successful cancer therapy. [My Copy] Anti-cancer agents in medicinal chemistry, Vol. 9, No. 1. (January 2009), pp. 66-76. by D. Pytel, T. Sliwinski, T. Poplawski, D. Ferriola, I. Majsterek posted to cancer inhibitor iressa kinase tk tki tyrosine by NaliniChilkov on 2009-01-25 07:38:13 as
	Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. [My Copy] Oncology (Williston Park, N.Y.), Vol. 20, No. 5 Suppl 2. (April 2006), pp. 15-25. by E. E. Vokes, E. Chu posted to antibody drug egfr epidermal erbitux factor growth inhibitor iressa kinase monoclonal receptor resistant tarceva tyrosine by NaliniChilkov on 2009-01-25 07:36:35 as
	Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. [My Copy] Cancer research, Vol. 64, No. 15. (1 August 2004), pp. 5355-5362. by S. Huang, E. A. Armstrong, S. Benavente, P. Chinnaiyan, P. M. Harari posted to and antibody cancer egfr erbitux head inhibitor iressa kinase neck oral tyrosine by NaliniChilkov on 2009-01-25 07:29:33 as
	ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. [My Copy] Proc Natl Acad Sci U S A, Vol. 102, No. 10. (8 March 2005), pp. 3788-3793. by J. A. Engelman, P. A. Jänne, C. Mermel, et al.J. Pearlberg, T. Mukohara, C. Fleet, K. Cichowski, B. E. Johnson, L. C. Cantley posted to akt erbb3 inhibitor iressa nsclc by pjasper on 2007-05-22 18:40:08 as
	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. [My Copy] PLoS Med, Vol. 2, No. 3. (March 2005) by W. Pao, V. A. Miller, K. A. Politi, et al.G. J. Riely, R. Somwar, M. F. Zakowski, M. G. Kris, H. Varmus posted to egfr iressa mutant resistance t790m tarceva by pjasper on 2007-05-10 20:41:10 as
	Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. [My Copy] Cancer Res, Vol. 61, No. 24. (15 December 2001), pp. 8887-8895. by S. L. Moulder, F. M. Yakes, S. K. Muthuswamy, R. Bianco, J. F. Simpson, C. L. Arteaga posted to egfr erbb2 inactive_dimer iressa by pjasper on 2007-05-10 20:38:57 as
	ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. [My Copy] Clin Cancer Res, Vol. 9, No. 4. (April 2003), pp. 1274-1283. by J. Anido, P. Matar, J. Albanell, et al.M. Guzmán, F. Rojo, J. Arribas, S. Averbuch, J. Baselga posted to egfr erbb2 erbb3 inactive_dimer iressa by pjasper on 2007-05-10 20:36:31 as along with 1 person brianb
	HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. [My Copy] Cancer Res, Vol. 65, No. 10. (15 May 2005), pp. 4253-4260. by A. Hirata, F. Hosoi, M. Miyagawa, et al.S. Ueda, S. Naito, T. Fujii, M. Kuwano, M. Ono posted to egfr erbb2 inhibitor iressa nsclc by pjasper on 2007-05-10 19:52:18 as along with 1 person js229
	Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib. [My Copy] Exp Cell Res, Vol. 313, No. 7. (15 April 2007), pp. 1361-1372. by X. Liu, D. L. Carlisle, M. C. Swick, A. Gaither-Davis, J. R. Grandis, J. M. Siegfried posted to egfr gastrin iressa resistance by pjasper on 2007-05-08 18:59:54 as
	The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines. [My Copy] Histochem Cell Biol, Vol. 127, No. 5. (May 2007), pp. 541-553. by Y. Nishimura, B. Bereczky, M. Ono posted to egfr internalization iressa by pjasper on 2007-05-08 18:56:46 as
	Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. [My Copy] Cancer Res, Vol. 67, No. 5. (1 March 2007), pp. 2325-2330. by R. Mulloy, A. Ferrand, Y. Kim, et al.R. Sordella, D. W. Bell, D. A. Haber, K. S. Anderson, J. Settleman posted to egfr iressa mutation nsclc by pjasper on 2007-05-08 18:52:47 as
	Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. [My Copy] Ann Oncol, Vol. 18, No. 4. (April 2007), pp. 752-760. by F. Hirsch, M. Varella-Garcia, F. Cappuzzo, et al.J. McCoy, L. Bemis, A. Xavier, R. Dziadziuszko, P. Gumerlock, K. Chansky, H. West, A. Gazdar, L. Crino, D. Gandara, W. Franklin, P. Bunn posted to amplification egfr inhibitor iressa nsclc by pjasper on 2007-05-08 18:46:53 as
	Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. [My Copy] Clin Cancer Res, Vol. 12, No. 24. (15 December 2006), pp. 7242-7251. by M. Ono, M. Kuwano posted to egfr inhibitor iressa review by pjasper on 2007-04-26 17:44:12 as
	Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. [My Copy] Clin Cancer Res, Vol. 12, No. 23. (1 December 2006), pp. 7117-7125. by B. A. Helfrich, D. Raben, M. Varella-Garcia, et al.D. Gustafson, D. C. Chan, L. Bemis, C. Coldren, A. Barón, C. Zeng, W. A. Franklin, F. R. Hirsch, A. Gazdar, J. Minna, P. A. Bunn posted to akt egfr genomics iressa mutation nsclc by pjasper on 2007-04-26 17:27:15 as
	Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib. [My Copy] Cancer Res, Vol. 66, No. 15. (1 August 2006), pp. 7708-7715. by M. P. Cunningham, H. Thomas, Z. Fan, H. Modjtahedi posted to colon icr62 inhibitor iressa novel by pjasper on 2007-04-25 21:48:28 as
	Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. [My Copy] Clin Cancer Res, Vol. 12, No. 13. (1 July 2006), pp. 3908-3914. by D. M. Jackman, B. Y. Yeap, L. V. Sequist, et al.N. Lindeman, A. J. Holmes, V. A. Joshi, D. W. Bell, M. S. Huberman, B. Halmos, M. S. Rabin, D. A. Haber, T. J. Lynch, M. Meyerson, B. E. Johnson, P. A. Jänne posted to deletion iressa mutation nsclc by pjasper on 2007-04-25 21:23:34 as
	Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. [My Copy] Clin Cancer Res, Vol. 12, No. 13. (1 July 2006), pp. 4103-4111. by K. Erjala, M. Sundvall, T. T. Junttila, et al.N. Zhang, M. Savisalo, P. Mali, J. Kulmala, J. Pulkkinen, R. Grenman, K. Elenius posted to erbb2 erbb3 inhibitor iressa resistance by pjasper on 2007-04-25 21:06:38 as
	EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer [My Copy] Oncogene, Vol. aop, No. current. by S. H. Choi, J. M. Mendrola, M. A. Lemmon, posted to activation egf-independent iressa mutation nsclc by pjasper on 2007-04-25 20:36:12 as
	Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations. [My Copy] J Biol Chem, Vol. 281, No. 52. (29 December 2006), pp. 40183-40192. by M. Perez-Torres, M. Guix, A. Gonzalez, C. L. Arteaga posted to iressa mutation resistance by pjasper on 2007-04-25 20:26:15 as
	Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. [My Copy] British journal of cancer, Vol. 95, No. 11. (4 December 2006), pp. 1504-1513. by H. Yokoyama, Y. Ikehara, Y. Kodera, et al.S. Ikehara, Y. Yatabe, Y. Mochizuki, M. Koike, M. Fujiwara, A. Nakao, M. Tatematsu, H. Nakanishi posted to erbb2 iressa resistance by pjasper on 2007-04-25 20:22:54 as along with 2 people mat956 klu
	Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. [My Copy] Genes Dev, Vol. 20, No. 11. (1 June 2006), pp. 1496-1510. by K. Politi, M. F. Zakowski, P. D. Fan, E. A. Schonfeld, W. Pao, H. E. Varmus posted to iressa mouse mutation nsclc by pjasper on 2007-04-25 20:09:14 as
	PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib. [My Copy] Cancer Res, Vol. 66, No. 10. (15 May 2006), pp. 5346-5353. by S. Ueda, Y. Basaki, M. Yoshie, et al.K. Ogawa, S. Sakisaka, M. Kuwano, M. Ono posted to akt iressa pten by pjasper on 2007-04-25 20:07:17 as
	Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. [My Copy] Int J Cancer, Vol. 119, No. 11. (1 December 2006), pp. 2557-2566. by C. Desbois-Mouthon, W. Cacheux, M. J. Blivet-Van Eggelpoël, et al.V. Barbu, L. Fartoux, R. Poupon, C. Housset, O. Rosmorduc posted to crosstalk igf iressa by pjasper on 2007-04-25 19:49:31 as
	AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib. [My Copy] Breast Cancer Res Treat, Vol. 102, No. 3. (May 2007), pp. 275-282. by M. R. Maiello, A. D'Alessio, A. De Luca, et al.A. Carotenuto, A. M. Rachiglio, M. Napolitano, L. Cito, A. Guzzo, N. Normanno posted to azd3409 breast iressa resistance by pjasper on 2007-04-25 19:45:44 as
	Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. [My Copy] Cancer Res, Vol. 66, No. 7. (1 April 2006), pp. 3802-3812. by M. S. Pino, M. Shrader, C. H. Baker, et al.F. Cognetti, H. Q. Xiong, J. L. Abbruzzese, D. J. McConkey posted to activation iressa pancreas tgfa by pjasper on 2007-04-25 19:33:03 as
	Gefitinib and the modulation of the signaling pathways downstream of epidermal growth factor receptor in human liver cancer cells. [My Copy] J Gastroenterol, Vol. 41, No. 2. (February 2006), pp. 166-176. by J. Okano, K. Matsumoto, T. Nagahara, Y. Murawaki posted to inhibitor iressa signaling by pjasper on 2007-04-25 19:26:09 as
	In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib. [My Copy] Biochem J, Vol. 397, No. 3. (1 August 2006), pp. 537-543. by K. Sakai, H. Yokote, K. Murakami-Murofushi, T. Tamura, N. Saijo, K. Nishio posted to deletion iressa mutant by pjasper on 2007-04-25 16:46:50 as
	Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. [My Copy] Cancer Res, Vol. 66, No. 2. (15 January 2006), pp. 944-950. by S. E. Witta, R. M. Gemmill, F. R. Hirsch, et al.C. D. Coldren, K. Hedman, L. Ravdel, B. Helfrich, R. Dziadziuszko, D. C. Chan, M. Sugita, Z. Chan, A. Baron, W. Franklin, H. A. Drabkin, L. Girard, A. F. Gazdar, J. D. Minna, P. A. Bunn posted to e-cadhering iressa nsclc by pjasper on 2007-04-25 16:19:49 as
	The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. [My Copy] J Cell Physiol, Vol. 207, No. 2. (May 2006), pp. 420-427. by N. Normanno, A. De Luca, M. R. Maiello, et al.M. Campiglio, M. Napolitano, M. Mancino, A. Carotenuto, G. Viglietto, S. Menard posted to iressa mapk resistance by pjasper on 2007-04-25 16:07:37 as
	High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. [My Copy] Cancer Res, Vol. 65, No. 24. (15 December 2005), pp. 11478-11485. by N. Fujimoto, M. Wislez, J. Zhang, et al.K. Iwanaga, J. Dackor, A. E. Hanna, S. Kalyankrishna, D. D. Cody, R. E. Price, M. Sato, J. W. Shay, J. D. Minna, M. Peyton, X. Tang, E. Massarelli, R. Herbst, D. W. Threadgill, I. I. Wistuba, J. M. Kurie posted to erbb2 erbb3 iressa ligands by pjasper on 2007-04-19 19:42:05 as
	Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib. [My Copy] Clin Cancer Res, Vol. 11, No. 24 Pt 1. (15 December 2005), pp. 8872-8879. by K. Ando, T. Ohmori, F. Inoue, et al.T. Kadofuku, T. Hosaka, H. Ishida, T. Shirai, K. Okuda, T. Hirose, N. Horichi, K. Nishio, N. Saijo, M. Adachi, T. Kuroki posted to iressa nsclc tnf by pjasper on 2007-04-19 19:40:33 as
	EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. [My Copy] Lung Cancer, Vol. 51, No. 3. (March 2006), pp. 363-368. by N. Yoshimura, S. Kudoh, T. Kimura, et al.S. Mitsuoka, K. Matsuura, K. Hirata, K. Matsui, S. Negoro, K. Nakagawa, M. Fukuoka posted to ekb569 inhibitor iressa nsclc by pjasper on 2007-04-19 19:23:32 as
	HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients [My Copy] British Journal of Cancer, Vol. aop, No. current. (15 November 2005) by F. Cappuzzo, L. Toschi, I. Domenichini, et al.S. Bartolini, G. L. Ceresoli, E. Rossi, V. Ludovini, A. Cancellieri, E. Magrini, L. Bemis, W. A. Franklin, L. Crino, P. A. Bunn, F. R. Hirsch, M. Varella-Garcia posted to amplification erbb3 iressa nsclc by pjasper on 2007-04-19 19:14:37 as
	Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer. [My Copy] Cancer Lett, Vol. 230, No. 1. (8 December 2005), pp. 33-46. by H. Nakamura, S. Takamori, T. Fujii, et al.M. Ono, H. Yamana, M. Kuwano, K. Shirouzu posted to herceptin inhibitor iressa nsclc by pjasper on 2007-04-19 19:02:16 as
	Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR [My Copy] Nature Genetics, Vol. 37, No. 12. (30 October 2005), pp. 1315-1316. by Daphne W. Bell, Ira Gore, Ross A. Okimoto, et al.Nadia Godin-Heymann, Raffaella Sordella, Roseann Mulloy, Sreenath V. Sharma, Brian W. Brannigan, Gayatry Mohapatra, Jeff Settleman, Daniel A. Haber posted to iressa mutation nsclc t790m by pjasper on 2007-04-19 19:00:48 as
	Blockade of epidermal growth factor receptors chemosensitizes breast cancer cells through up-regulation of Bnip3L. [My Copy] Cancer Res, Vol. 65, No. 18. (15 September 2005), pp. 8151-8157. by P. J. Real, A. Benito, J. Cuevas, et al.M. T. Berciano, A. de Juan, P. Coffer, J. Gomez-Roman, M. Lafarga, J. M. Lopez-Vega, J. L. Fernandez-Luna posted to bnip3l breast iressa by pjasper on 2007-04-18 21:20:24 as
	Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R. [My Copy] PLoS Med, Vol. 2, No. 9. (September 2005) by C. H. Gow, J. Y. Shih, Y. L. Chang, C. J. Yu posted to iressa l858r mutation by pjasper on 2007-04-18 21:16:11 as
	Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. [My Copy] J Clin Oncol, Vol. 23, No. 31. (1 November 2005), pp. 8081-8092. by D. W. Bell, T. J. Lynch, S. M. Haserlat, et al.P. L. Harris, R. A. Okimoto, B. W. Brannigan, D. C. Sgroi, B. Muir, M. J. Riemenschneider, R. B. Iacona, A. D. Krebs, D. H. Johnson, G. Giaccone, R. S. Herbst, C. Manegold, M. Fukuoka, M. G. Kris, J. Baselga, J. S. Ochs, D. A. Haber posted to amplification iressa mutation nsclc by pjasper on 2007-04-18 21:08:24 as
	Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants [My Copy] Oncogene, Vol. aop, No. current. by Y. R. Chen, Y. N. Fu, C. H. Lin, et al.S. T. Yang, S. F. Hu, Y. T. Chen, S. F. Tsai, S. F. Huang, posted to activation iressa mutant by pjasper on 2007-04-18 21:07:17 as
	Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. [My Copy] PLoS Med, Vol. 2, No. 11. (November 2005) by H. Greulich, T. H. Chen, W. Feng, et al.P. A. Jänne, J. V. Alvarez, M. Zappaterra, S. E. Bulmer, D. A. Frank, W. C. Hahn, W. R. Sellers, M. Meyerson posted to iressa mutant transformation by pjasper on 2007-04-18 20:56:06 as
	Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII [My Copy] British Journal of Cancer, Vol. aop, No. current. (27 September 2005) by M. W. Pedersen, N. Pedersen, L. H. Ottesen, H. S. Poulsen posted to iressa v3 by pjasper on 2007-04-18 20:54:47 as
	Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. [My Copy] J Natl Cancer Inst, Vol. 97, No. 16. (17 August 2005), pp. 1185-1194. by T. Mukohara, J. A. Engelman, N. H. Hanna, et al.B. Y. Yeap, S. Kobayashi, N. Lindeman, B. Halmos, J. Pearlberg, Z. Tsuchihashi, L. C. Cantley, D. G. Tenen, B. E. Johnson, P. A. Jänne posted to c225 iressa nsclc by pjasper on 2007-04-18 20:44:20 as
	Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. [My Copy] J Clin Oncol, Vol. 23, No. 22. (1 August 2005), pp. 5007-5018. by F. Cappuzzo, M. Varella-Garcia, H. Shigematsu, et al.I. Domenichini, S. Bartolini, G. L. Ceresoli, E. Rossi, V. Ludovini, V. Gregorc, L. Toschi, W. A. Franklin, L. Crino, A. F. Gazdar, P. A. Bunn, F. R. Hirsch posted to amplification erbb2 iressa nsclc by pjasper on 2007-04-18 20:38:35 as
	Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. [My Copy] Cancer Res, Vol. 65, No. 15. (1 August 2005), pp. 6943-6949. by C. H. Yang, C. J. Huang, C. S. Yang, et al.Y. C. Chu, A. L. Cheng, J. Whang-Peng, P. C. Yang posted to atp iressa by pjasper on 2007-04-18 20:34:32 as
	Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. [My Copy] Proc Natl Acad Sci U S A, Vol. 102, No. 31. (2 August 2005), pp. 11011-11016. by T. A. Carter, L. M. Wodicka, N. P. Shah, et al.A. M. Velasco, M. A. Fabian, D. K. Treiber, Z. V. Milanov, C. E. Atteridge, W. H. Biggs, P. T. Edeen, M. Floyd, J. M. Ford, R. M. Grotzfeld, S. Herrgard, D. E. Insko, S. A. Mehta, H. K. Patel, W. Pao, C. L. Sawyers, H. Varmus, P. P. Zarrinkar, D. J. Lockhart posted to iressa mutant by pjasper on 2007-04-18 20:30:01 as along with 1 person preeves
	Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. [My Copy] J Clin Oncol, Vol. 23, No. 28. (1 October 2005), pp. 6829-6837. by T. Takano, Y. Ohe, H. Sakamoto, et al.K. Tsuta, Y. Matsuno, U. Tateishi, S. Yamamoto, H. Nokihara, N. Yamamoto, I. Sekine, H. Kunitoh, T. Shibata, T. Sakiyama, T. Yoshida, T. Tamura posted to iressa mutation nsclc by pjasper on 2007-04-18 19:31:19 as
	Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. [My Copy] Breast Cancer Res, Vol. 7, No. 4. (2005) by A. Camirand, M. Zakikhani, F. Young, M. Pollak posted to apoptosis breast igf iressa by pjasper on 2007-04-18 18:37:59 as

Note: You may cite this page as: http://www.citeulike.org/tag/iressa

Result page: 1 2 Next

Sort by:
Order:	Default Ascending Descending
Empty fields:	Default First Last

nsclc	20
egfr	13
inhibitor	12
mutation	10
resistance	8
erbb2	7
cancer	6
erbb3	5
mutant	5
amplification	4
breast	4
activation	3
akt	3
kinase	3
lung	3
tarceva	3
tyrosine	3
antibody	2
deletion	2
erbitux	2
gefitinib	2
igf	2
inactive_dimer	2
t790m	2
aktpkb	1
apoptosis	1
atp	1
azd3409	1
bnip3l	1
c225	1
colon	1
crosstalk	1
drug	1
e-cadhering	1
egf	1
egf-independent	1
ekb569	1
epidermal	1
erbb2gefitibin	1
erlotinib	1
factor	1
gastrin	1
genomics	1
gerifinib	1
growth	1
head	1
herceptin	1
icr62	1
internalization	1
l858r	1
ligands	1
lungcancer	1
mapk	1
mcf-7	1
monoclonal	1
morant	1
mouse	1
neck	1
novel	1
oral	1
pancreas	1
pi3k	1
pten	1
receptor	1
resistant	1
review	1
signaling	1
tamoxifen	1
tgfa	1
tk	1
tki	1
tnf	1
transformation	1
v3	1
zd1839	1

Tag iressa [52 articles] Export Sort

Related Tags